Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Priya Rastogi, MD, considers the interchangeability of CDK 4/6 inhibitors

Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, on whether certain CDK 4/6 inhibitors are interchangeable in the management of HR+, HER2- node positive high risk early breast cancer

Tags: BreastSABCS Conference Coverage

Published: 17 December 2020

Recent Videos: Breast

video

Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 ...

video

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating ...

video

Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) ...

video

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding ...

video

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER ...

video

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented ...

video

Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors

Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key ...

video

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates ...

video

Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE

Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts ...

video

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy

Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses ...

Related Videos

video-image

Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors

video-image

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

video-image

Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer

video-image

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer

video-image

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

video-image

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020

video-image

Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors

video-image

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

video-image

Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE

video-image

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy

video-image

Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer

video-image

Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer

video-image

Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer

video-image

Priya Rastogi, MD, shares the design and outcomes of the monarchE clinical trial from SABCS 2020

video-image

Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020

video-image

Hope Rugo, MD, provides perspective on the clinical progress of CDK 4/6 inhibitors in breast cancer

video-image

Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020

video-image

Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355

video-image

Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355

video-image

Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020

video-image

Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat

video-image

Erika Hamilton, MD, considers the role of NGS testing for breast cancer patients

video-image

Erika Hamilton, MD, regarding the use of CDK 4/6 inhibitors in clinical practice

video-image

Erika Hamilton, MD, on promising treatment options in the management of HER2+ advanced breast cancer

video-image

Erika Hamilton, MD, provides perspective on the latest immunotherapy treatment trends in TNBC

video-image

Erika Hamilton, MD, discusses findings from the MARIO-3 clinical trial presented at the 2020 SABCS

video-image

Debra Patt, MD, PhD, MBA, speculates on exciting data in TNBC coming out of SABCS 2020

video-image

Debra Patt, MD, PhD, MBA, summarizes data from the ExteNET trial presented at SABCS 2020

video-image

Debra Patt, MD, PhD, MBA, comments on findings from the KEYNOTE-355 trial

video-image

Debra Patt, MD, PhD, MBA, provides perspective on the latest immunotherapy treatment trends in TNBC

video-image

Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

video-image

Julie Gralow, MD, offers opinion on immunotherapy treatment trends in the management of TNBC

video-image

Julie Gralow, MD, regarding the ITOMIC trial data from the 2020 San Antonio Breast Cancer Symposium

video-image

Julie Gralow, MD, elaborates on the issue of resistance to endocrine therapies

video-image

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium

video-image

Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study

video-image

Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials

video-image

Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

video-image

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

video-image

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

video-image

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

video-image

Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib

video-image

Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020

video-image

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

video-image

Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium

video-image

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

video-image

Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer

video-image

Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer

video-image

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard

video-image

Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients